30 Day Trial

Organogenesis Acquiring NuTech Medical

Share:

Organogenesis is acquiring NuTech Medical, developer of amniotic products with application in soft tissue and bone regeneration.

NuTech Medical's portfolio includes Affinity fresh amniotic allograft; NuShield dehydrated terminally-sterilized allograft and NuCel and ReNu cryopreserved allografts. NuTech Medical's non-biologics product line will remain as a separate company, NuTech Spine.

NuTech Medical will continue existing operations as a division of Organogenesis, focused on surgical biologics. It will continue to develop and distribute products from existing facilities in Birmingham, Alabama, growing its present 150-rep sales network. NuTech's President & CEO, Howard Walthall, will now preside over Organogenesis' Surgical Division and also serve as Senior Vice President for Strategy and Development.

Sources: Organogenesis, Inc.; ORTHOWORLD Inc.